Researchers at the Department of Experimental Pharmacology at the University of Naples, Italy, conducted a study to assess the effect of cannabidiol on intestinal inflammation. Studying both humans suffering from ulcerative colitis (UC) and mice, they observed that “CBD targets enteric reactive gliosis, counteracts the inflammatory environment induced by LPS in mice and in human colonic cultures derived from UC patients.” The research group concluded that “CBD is a new therapeutic strategy to treat inflammatory bowel diseases.” Although more research is needed to clarify issues such as dosage and long-term tolerability, current evidence shows CBD is an effective therapy for many GI disorders.
Current treatments for GI disorders include extremely limited diets, pharmaceuticals and even surgery. Those who suffer from GI disorders often experience a diminished quality of life due to the embarrassing side effects GI disorders can pose. Finding an effective, natural therapy option, with little to no side effects, such as CBD, would be a major breakthrough for those currently suffering from gastrointestinal disorders.
To learn more about this study, click here.